Anti-staphylococcal humoral immune response in persistent nasal carriers and noncarriers of Staphylococcus aureus
- PMID: 19199541
- DOI: 10.1086/596743
Anti-staphylococcal humoral immune response in persistent nasal carriers and noncarriers of Staphylococcus aureus
Abstract
Background: Persistent carriers have a higher risk of Staphylococcus aureus infections than noncarriers but a lower risk of bacteremia-related death. Here, the role played by anti-staphylococcal antibodies was studied.
Methods: Serum samples from 15 persistent carriers and 19 noncarriers were analyzed for immunoglobulin (Ig) G, IgA, and IgM binding to 19 S. aureus antigens, by means of Luminex technology. Nasal secretions and serum samples obtained after 6 months were also analyzed.
Results: Median serum IgG levels were significantly higher in persistent carriers than in noncarriers for toxic shock syndrome toxin (TSST)-1 (median fluorescence intensity [MFI] value, 11,554 vs. 4291; P < .001) and staphylococcal enterotoxin (SE) A (742 vs. 218; P < .05); median IgA levels were higher for TSST-1 (P < .01), SEA, and clumping factor (Clf) A and B (P < .05). The in vitro neutralizing capacity of anti-TSST-1 antibodies was correlated with the MFI value (R(2) = 0.93) and was higher in persistent carriers (90.6% vs. 70.6%; P < .05). Antibody levels were stable over time and correlated with levels in nasal secretions (for IgG, R(2) = 0.87; for IgA, R(2) = 0.77).
Conclusions: Antibodies to TSST-1 have a neutralizing capacity, and median levels of antibodies to TSST-1, SEA, ClfA, and ClfB are higher in persistent carriers than in noncarriers. These antibodies might be associated with the differences in the risk and outcome of S. aureus infections between nasal carriers and noncarriers.
Similar articles
-
Detection of specific antibodies in cord blood, infant and maternal saliva and breast milk to staphylococcal toxins implicated in sudden infant death syndrome (SIDS).FEMS Immunol Med Microbiol. 2004 Sep 1;42(1):94-104. doi: 10.1016/j.femsim.2004.06.010. FEMS Immunol Med Microbiol. 2004. PMID: 15325402
-
The effect of Staphylococcus aureus carriage in late pregnancy on antibody levels to staphylococcal toxins in cord blood and breast milk.FEMS Immunol Med Microbiol. 2008 Oct;54(1):137-43. doi: 10.1111/j.1574-695X.2008.00463.x. Epub 2008 Jul 28. FEMS Immunol Med Microbiol. 2008. PMID: 18665847
-
Reclassification of Staphylococcus aureus nasal carriage types.J Infect Dis. 2009 Jun 15;199(12):1820-6. doi: 10.1086/599119. J Infect Dis. 2009. PMID: 19419332
-
Staphylococcus aureus. The persistent pathogen (second of two parts).N Engl J Med. 1984 May 31;310(22):1437-42. doi: 10.1056/NEJM198405313102206. N Engl J Med. 1984. PMID: 6371536 Review. No abstract available.
-
Immune proteomics of Staphylococcus aureus.Proteomics. 2011 Aug;11(15):3221-31. doi: 10.1002/pmic.201100010. Epub 2011 Jun 28. Proteomics. 2011. PMID: 21710570 Review.
Cited by
-
Combining in vitro protein detection and in vivo antibody detection identifies potential vaccine targets against Staphylococcus aureus during osteomyelitis.Med Microbiol Immunol. 2017 Feb;206(1):11-22. doi: 10.1007/s00430-016-0476-8. Epub 2016 Sep 14. Med Microbiol Immunol. 2017. PMID: 27629411 Free PMC article.
-
Longitudinal analysis of methicillin-resistant and methicillin-susceptible Staphylococcus aureus carriage in healthy adolescents.J Clin Microbiol. 2013 Aug;51(8):2508-14. doi: 10.1128/JCM.00572-13. Epub 2013 May 15. J Clin Microbiol. 2013. PMID: 23678067 Free PMC article.
-
Vaccines for healthcare associated infections without vaccine prevention to date.Vaccine X. 2022 May 5;11:100168. doi: 10.1016/j.jvacx.2022.100168. eCollection 2022 Aug. Vaccine X. 2022. PMID: 35600984 Free PMC article.
-
Children with invasive Staphylococcus aureus disease exhibit a potently neutralizing antibody response to the cytotoxin LukAB.Infect Immun. 2014 Mar;82(3):1234-42. doi: 10.1128/IAI.01558-13. Epub 2013 Dec 30. Infect Immun. 2014. PMID: 24379282 Free PMC article.
-
Inhibition of protective immunity against Staphylococcus aureus infection by MHC-restricted immunodominance is overcome by vaccination.Sci Adv. 2020 Apr 1;6(14):eaaw7713. doi: 10.1126/sciadv.aaw7713. eCollection 2020 Apr. Sci Adv. 2020. PMID: 32270029 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous